×

Exceptional PartnershipsDynamic Growth

Annual Report 2023

Syngene at a Glance

*1 USD = Rs 80.4
About Syngene

Finding solutions through partnerships

Syngene is an integrated research, development, and manufacturing services organization offering scientific solutions to provide advances in human and animal health, specialty chemicals, and consumer goods. We offer client partnerships that range from a single specialist service to an end-to-end program, accelerating the progress of a molecule to market through seamless integration.

Message from our

Chairperson

Kiran Mazumdar Shaw

Full year revenue from operations growth was 23% at Rs 3,193 Cr (USD 397 Mn)3 and profit after tax before exceptional items grew by 10% to Rs 464 Cr (USD 58 Mn), exceeding the upgraded guidance provided earlier in the year on both measures.

Message from our

Managing Director and Chief Executive Officer

Jonathan Hunt

We signed a 10‑year partnership with Zoetis for commercial manufacturing of a monoclonal antibody for animal health and celebrated the 25th anniversary of our partnership with Bristol Myers Squibb for innovative discovery research in human health.

Message from our

Chief Financial Officer

Sibaji Biswas

Development and Manufacturing Services grew by 28% year-on-year. Growth was driven by repeat orders from existing clients as well as an increase in the number of collaborations with emerging biopharma companies.

Our Services

Strategic Priorities

Read More

Our Value Creation Model

Read More

Our WorkforceDynamic growth powered by our workforce

Read More

Showcases

Download Center

Board Report

Consolidated Financial Statements

Management Discussion and Analysis

Standalone Financial Statements

Business Responsibility and Sustainability Report

AGM Notice

Corporate Governance Report

Glossary

Annual Report 2023